Literature DB >> 21348557

Analysis of venous thromboprophylaxis duration and outcomes in orthopedic patients.

Philip S Wells1, Bijan J Borah, Nishan Sengupta, Dylan Supina, Heather P McDonald, Louis M Kwong.   

Abstract

BACKGROUND: Venous thromboembolism (VTE) following total hip replacement (THR) and total knee replacement (TKR) surgery imposes significant health and economic burden.
OBJECTIVE: To examine the impact of thromboprophylaxis duration on deep vein thrombosis (DVT), pulmonary embolism (PE), total VTE (DVT and PE), and bleeding events among THR/TKR patients.
METHODS: A retrospective study (April 1, 2004, to December 31, 2006) was conducted using a US health plan claims database linked to an inpatient database containing medication use. Outcomes were compared using χ2 tests; predictors of outcomes were analyzed using multivariate logistic regression.
RESULTS: Of 3497 patients, 3195 (91%) received thromboprophylaxis for =1 day postsurgery. Most patients (67%) received short-duration (1-14 days) rather than extended-duration (>14 days) thromboprophylaxis. The incidence of thromboembolic and bleeding events was higher in those who received short-duration thromboprophylaxis: DVT (2.84% vs 1.24%; P = .0038), PE (1.12% vs 0.19%; P = .0052), total VTE (3.96% vs 1.43%; P <.0001), and major bleeding (1.68% vs 0.38%; P = .0011). Multivariate logistic regressions (adjusted for observed demographic and clinical characteristics) revealed similar results. Baseline comorbidity score was significantly associated with major bleeding; most of the bleeding events in those who received short-duration thromboprophylaxis occurred within the first 14 days.
CONCLUSIONS: In this database analysis of patients who had undergone THR/TKR surgery, a large proportion of patients did not receive the minimum duration of thromboprophylaxis recommended by the guidelines. Extended-duration thromboprophylaxis was associated with a significantly lower risk of DVT, PE, and VTE compared with short-duration thromboprophylaxis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21348557

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  8 in total

1.  NICE thromboprophylaxis guidelines are not associated with increased pericardial effusion after surgery of the proximal thoracic aorta.

Authors:  I A Rahman; A Hussain; A Davies; A J Bryan
Journal:  Ann R Coll Surg Engl       Date:  2013-09       Impact factor: 1.891

2.  Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.

Authors:  Aurea Duran; Nishan Sengupta; Alexander Diamantopoulos; Fiona Forster; Louis Kwong; Michael Lees
Journal:  Pharmacoeconomics       Date:  2012-02-01       Impact factor: 4.981

3.  Preoperative versus postoperative initiation of thromboprophylaxis following major orthopedic surgery: safety and efficacy of postoperative administration supported by recent trials of new oral anticoagulants.

Authors:  Carsten Perka
Journal:  Thromb J       Date:  2011-11-16

Review 4.  Risk factors for venous thromboembolism of total hip arthroplasty and total knee arthroplasty: a systematic review of evidences in ten years.

Authors:  Zi-hao Zhang; Bin Shen; Jing Yang; Zong-ke Zhou; Peng-de Kang; Fu-xing Pei
Journal:  BMC Musculoskelet Disord       Date:  2015-02-10       Impact factor: 2.362

Review 5.  Meta-analysis and suggested guidelines for prevention of venous thromboembolism (VTE) in foot and ankle surgery.

Authors:  James D F Calder; Richard Freeman; Erica Domeij-Arverud; C Niek van Dijk; Paul W Ackermann
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2016-03-18       Impact factor: 4.342

6.  The effect of new oral anticoagulants and extended thromboprophylaxis policy on hip and knee arthroplasty outcomes: observational study.

Authors:  Alex Bottle; Emeka Oragui; Elizabeth Pinder; Paul Aylin; Mark Loeffler
Journal:  Arthroplast Today       Date:  2015-06-23

7.  Is aspirin still relevant as a single pharmacological agent for venous thromboembolism prophylaxis post hip and knee arthroplasty surgery: A retrospective review.

Authors:  Jacques Pretorius; Nouman Nemat; Imran Azeem; Tony Shaju; Sayed Nadeem; Yasir Hammad
Journal:  SICOT J       Date:  2022-06-28

8.  Analysis of disease patterns and cost of treatments for prevention of deep venous thrombosis after total knee or hip replacement: results from the Practice Analysis of THromboprophylaxis after Orthopaedic Surgery (PATHOS) study.

Authors:  Luca Degli Esposti; Guido Didoni; Teresa Simon; Stefano Buda; Diego Sangiorgi; Ezio Degli Esposti
Journal:  Clinicoecon Outcomes Res       Date:  2012-12-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.